Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Bio-One Updates Mergers Strategy.


Business Editors/Health & Medical Writers

Bio-One Corporation (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
:BICO BICO Bicolor ) ("Bio-One" or the "Company") has revised its strategy to become a significant part of the consolidation in the nutritional supplements Nutritional Supplements Definition

Nutritional supplements include vitamins, minerals, herbs, meal supplements, sports nutrition products, natural food supplements, and other related products used to boost the nutritional content of the diet.
 industry. Through aggregation, Bio-One has initiated its plan to acquire at least one manufacturing business and select marketing companies that meet strict criteria. Independent research has revealed that 90% of the marketing companies outsource the manufacturing of their products. Approximately 40% of the marketing companies' sales can be captured as manufacturing revenue for the internally owned manufacturing business. Bio-One has embarked on the first stage of its consolidation program by targeting a group of well-managed companies representing EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) A metric used to show a company's profitability, but not its cash flow. EBITDA became popular in the 1980s to show the potential profitability of leveraged buyouts, but has become  of $5 to $7 million with revenues in excess of $45 million. These mergers are scheduled to be completed through a share exchange in the next 90 - 120 days. The Company intends to then pursue an international trade agreement to gather additional markets for its wholly owned subsidiaries' products through a planned strategic alliance with an internationally known trading company. This trading company which operates on a worldwide basis initiated contact with Bio-One management. Subsequent to this occurring, senior equity financing Equity Financing

The act of raising money for company activities by selling common or preferred stock to individual or institutional investors. In return for the money paid, shareholders receive ownership interests in the corporation.
 will be considered and discussed with those institutional investors Institutional Investor

A non-bank person or organization that trades securities in large enough share quantities or dollar amounts that they qualify for preferential treatment and lower commissions.
 who have previously and continue to express an interest in participating in the future growth of Bio-One.

Business Summary

Bio-One Corporation is an emerging growth company that is embarking on building a very significant business in the nutritional supplements industry via vertical integration mergers and marketing consolidation in Florida and the Southeast. The Company's home state, Florida, ranks second only to California in nutritional supplement sales and ranks first nationally in per capita [Latin, By the heads or polls.] A term used in the Descent and Distribution of the estate of one who dies without a will. It means to share and share alike according to the number of individuals.  consumption. The Company's goal is threefold; 1) to uniquely serve people worldwide who desire vitality and longevity; 2) to interface a quality and value growth philosophy through mergers and consolidation; 3) to provide an outstanding return on investment for Company shareholders.

Certain statements released by Bio-One Corporation that are forward-looking statements are made pursuant to the safe harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
 provisions of the Private Securities Reform Act of 1995. Editors and investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the Company's business prospects and performance. These include, but are not limited to, economic, competitive, governmental, technological and other risks detailed in the company's registration statements and periodic reports filed with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

For a live CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  interview, go to http://www.macreport.net
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 26, 2002
Words:423
Previous Article:Clareon Chairman and CEO Named a Finalist for Mass eComm 10; Paul Walsh Named One of Twenty Finalists for the Coveted Leadership Award.
Next Article:MeriStar Hospitality Corporation Declares Second-Quarter Dividend.



Related Articles
BioOne, Inc. (News in Brief).
New MRG Report: Pharmaceutical Firms Accelerating Product Development, Reducing R&D Through Bio-chip Ventures; Drug Manufacturers Set to Slash 10-15...
Selected trade and professional publication and online services, start-up or announced, first quarter, 2002.
Bio-One Receives $10 Million Commitment.
Bio-One Receives SEC Registration Statement Approval.
Two Major STM Content Aggregators Sign With Infotrieve; BioOne and Allen Press Offer Infotrieve's Worldwide Users Access To Articles From Hundreds of...
Cerus and BioOne Sign Letter of Intent for Commercialization of INTERCEPT Plasma in Asian Region.
Copyright Clearance Center and BioOne Partner to Expand Market Reach For Small Science Publishers.
Cerus and BioOne Enter Agreement for Commercialization of INTERCEPT Plasma; BioOne to Market Pathogen Inactivation for Both Platelets and Plasma in...
Cerus Corporation Receives Milestone Payment From BioOne.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles